Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

SYM S055 - Psoriasis

Open admission to eligible categories, no tuition or ticket


Date: Tuesday, March 25

CME Credits: 3.00

Location: Mile High Ballroom 4DEF

Time: 9:00 AM - 12:00 PM

Director: Craig A. Elmets, MD, FAAD

  • Kelly M. Cordoro, MD, FAAD - Handout
  • Kenneth B. Gordon, MD, FAAD
  • Heidi H. Kong, MD, MHS, FAAD
  • John Y. M. Koo, MD, FAAD - Handout
  • Mark Lebwohl, MD, FAAD - Handout
  • Frank Nestle - Handout
  • Abrar A. Qureshi, MD, MPH, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Summarize the most current information about the long term effects of biologic therapies and the status of new drugs that are in clinical trials.
  • Discuss current concepts of the pathogenesis of psoriasis.
  • List effective methods of managing psoriasis in the pediatric population.

This symposium will review the latest concepts of the pathogenesis of psoriasis. It will address biologic therapy and clinical trials investigating new forms of treatment. There will be a review of the long term consequences of biologic therapies. Psoriasis in children will be discussed. There will also be an appraisal of the current role of phototherapy in the care of psoriatic patients.


  • Nestle FO, Kaplan DH, Barker J.Psoriasis. N Engl J Med. 2009 Jul 30;361(5):496-509.
  • Guidelines of care for the management of psoriasis and psoriatic arthritis (six parts). JAAD 58:826-50, 2008; 58:851-64, 2008; 60:643-59, 2009; 61:451-85, 2009; 62:114-35, 2010; 65:137-74, 2011.
  • Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-1189. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-1199.


Tuesday, March 25
9:00 AMCurrent Understanding of Psoriasis Pathogenesis / Dr. Nestle
9:25 AMPotential Contribution of the Microbiome to Psoriasis / Dr. Kong
9:40 AMChallenges of Managing Psoriasis in the Pediatric Population / Dr. Cordoro
10:05 AMPsoriasis Co-morbidities: From Population Studies to Clinical Practice / Dr. Qureshi
10:30 AMPhototherapy in the Age of Biologics / Dr. Koo
10:50 AMTopical Therapy of Psoriasis: Past, Present and Future / Dr. Elmets
11:10 AMNew Systemic Agents for Psoriasis / Dr. Lebwohl
11:35 AMWhat are the Long Term Risks of Biologics for Psoriasis? / Dr. Gordon